Coronavirus (COVID-19) Treatment

The coronavirus (COVID-19) pandemic is unprecedented and is placing huge demands on the whole healthcare system. The situation is ongoing and rapidly changing.

The Clinical Policies and Decisions team have created this section of the website to host links to national websites for coronavirus related information.

Points to note:

  • GP's are not expected to prescribe or supply nMABs or antivirals
  • Majority of patients identified centrally and will be contacted by the CMDU
  • The pathway describes the national policy which has been locally adapted
COVID-19 Community Based Treatments Content Summary

JUCD CMDU pathway

Information on the local Derbyshire CMDU pathway 

JUCD COVID vaccine incident form

The purpose of this form is to identify why the incident occurred and action that has been taken to prevent similar incidents 

COVID-19 Medicine Delivery Unit (CMDU)

There are a modest number of patients who will not be identified automatically.

Referral can be made to the local CMDU service via the Electronic Referral Service, or via the direct number used for Red Hub referrals 0300 1000 432 or by emailing UCD.admin@nhs.net.

Please include:

  • Patient details
  • NHS number
  • Underlying qualifying clinical condition
  • Date of symptom onset
  • Date of PCR
  • Where possible, also include a copy of the PCR pathology report

Out of Area information can be found here 

 

National Guidance Content summary
COVID-19: information and advice for health and care professionals

GOV.UK - Background information and advice on coronavirus (COVID-19) for health and care professionals

Higher-risk patients eligible for COVID-19 treatments: independent advisory group report (March 2023)

Update to the independent advisory group report that identifies which patient groups are at highest risk of serious illness from COVID-19 and would benefit from new COVID-19 treatments.

Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Evidence-based recommendations on casirivimab plus imdevimab (Ronapreve), nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
COVID-19 rapid guideline: Managing COVID-19

This guideline covers the management of COVID-19 for babies, children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.